# DIAL (NCT05255302)

> De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05255302
- Phase: PHASE2, PHASE3
- Status: RECRUITING
- Sponsor: Intergroupe Francophone de Cancerologie Thoracique
- Conditions: Metastatic NSCLC
- Interventions: Pembrolizumab before randomization; Chemotherapy; Pemetrexed; Pembrolizumab after randomization
- Enrollment: 1360
- Primary outcome: Phase II: 18-month overall survival (OS)
- Primary outcome: Phase III: overall survival

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 9

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=dial-nct05255302

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05255302", "email": "<work email>"}; the inbox owner confirms by the emailed link.